Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK's Zejula Poised To Take On Lynparza In First-Line Ovarian Cancer

Executive Summary

The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.

You may also be interested in...



GSK Braces For A Hit To Its Vaccines Business Despite A Strong First Quarter

Stay-at-home restrictions due to COVID-19 have started to impact the company's vaccines business, including the big growth driver Shingrix.

ESMO Preview: Five Key Oncology Battlegrounds To Watch

GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.

GSK's New US Pharmaceuticals President Martinez-Davis Brings Oncology Experience

US Pharmaceuticals President Jack Bailey will step down, to be succeeded by Maya Martinez-Davis, currently at Merck KGAA.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131647

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel